Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Europa
Indivior PLC
Nieuws
Indivior PLC
INDV
LON
: INDV
| ISIN: GB00BN4HT335
21/05/2024
1.328,00 GBX
(-0,38%)
(-0,38%)
21/05/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Dividend
Technische analyse
TA
Toon enkel gratis nieuws
25 april 2024 ·
Indivior Announces Q1 2024 Financial Results
· Persbericht
11 maart 2024 ·
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
· Persbericht
29 februari 2024 ·
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation
· Persbericht
22 februari 2024 ·
Indivior Announces Q4 / FY 2023 Financial Results
· Persbericht
9 november 2023 ·
Indivior Announces Q3 2023 Financial Results
· Persbericht
11 oktober 2023 ·
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
· Persbericht
26 september 2023 ·
Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada
· Persbericht
21 augustus 2023 ·
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims
· Persbericht
27 juli 2023 ·
Indivior Announces Q2/H1 2023 Financial Results
· Persbericht
14 juni 2023 ·
Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence
· Persbericht
12 juni 2023 ·
Indivior to Commence Trading on Nasdaq
· Persbericht
2 juni 2023 ·
Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims
· Persbericht
25 mei 2023 ·
Indivior To Participate In Upcoming Investor Conferences
· Persbericht
23 mei 2023 ·
Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th
· Persbericht
23 mei 2023 ·
Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl
· Persbericht
27 april 2023 ·
Indivior Announces Q1 2023 Financial Results
· Persbericht
25 april 2023 ·
Indivior To Participate In Bank of America Global Healthcare Conference 2023
· Persbericht
2 maart 2023 ·
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
· Persbericht
16 februari 2023 ·
FY 2022 Financial Results Announced
· Persbericht
7 december 2022 ·
Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe